A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS) | Semantic Scholar
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid
Alex A. Adjei, MD, PhD Designing Phase I Trials with Targeted Agents: Challenging Tradition. - ppt download
Early phase clinical trials to identify optimal dosing and safety
Stephen V Liu, MD on Twitter: "#OncoAlert #AACR20 Dose escalation of TAK-788 (mobocertinib) established MTD of 160mg qday. DLTs were 1 case each of grade 3 diarrhea, grade 3 mucositis, grade 3
Sequential or combined designs for Phase I/II clinical trials? A simulation study - Caroline Rossoni, Aurélie Bardet, Birgit Geoerger, Xavier Paoletti, 2019
Expansion Cohorts Guidance Balances Drug Development With Safety, Rigor
Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram
Phase I study design with dose-escalation and dose-expansion phases | Download Scientific Diagram
Schematic overview of the dose escalation cohorts. Three to nine... | Download Scientific Diagram
stro-ex992_8.pptx.htm
SEC Filing | Blueprint Medicines Corp.
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) | Journal for ImmunoTherapy of Cancer | Full Text
Dose escalation. The dose escalation was performed in both intra and... | Download Scientific Diagram
The Expansion Phase of Phase I Oncology Trials
Phase I study design with dose-escalation and dose-expansion phases | Download Scientific Diagram
Protocol B7861002 A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS P
Figure 1 from Design considerations for dose-expansion cohorts in phase I trials. | Semantic Scholar
Phase I/II Dose-Escalation Trial of Daratumumab for Relapsed/Refractory Multiple Myeloma | Research To Practice
SEC Filing | Harpoon Therapeutics, Inc.
Study design. a Framework for the dose-escalation and dose-expansion... | Download Scientific Diagram
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer - Yap - 2020 - Cancer Science - Wiley Online Library
P01.06 CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase - Journal of Thoracic Oncology
Randomised Phase 1 clinical trials in oncology | British Journal of Cancer
Cancers | Free Full-Text | A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
